An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Conditions

Diffuse Large B-Cell Lymphoma

Brief summary

This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL). Data will be collected from each patient during the 6 months of induction treatment and for up to 3 years of follow-up.

Jianqiu Wu, Yongping Song, Liping Su, Mingzhi Zhang, Wei Li et al. (25 authors)

Chinese Medical Journal2018-07-2427 citations

10.4103/0366-6999.237401

Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study.

Wu J, Song Y, Su L, Xu L, Chen T, Zhao Z, Zhang M, Li W, Hu Y, Zhang X, Gao Y, Niu Z, Feng R, Wang W, Peng J, Li X, Ouyang X, Wu C, Zhang W, Zeng Y, Xiao Z, Liang Y, Zhuang Y, Wang J, Sun Z, Bai H, Cui T, Feng J.

2016-07-2611 citations

10.1186/s12885-016-2523-7

A Prospective, Observational Study on the Safety and Effectiveness of Rituximab Plus Chemotherapy As the First-Line Treatment of Diffuse Large B-Cell Lymphoma

Jifeng Feng, Jianqiu Wu, Yongping Song, Liping Su, Mingzhi Zhang et al. (25 authors)

Blood2014-12-06

10.1182/blood.v124.21.5475.5475

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Histologically confirmed CD20+ diffuse large B-cell lymphoma or follicular lymphoma * Treatment with MabThera/Rituxan as per locally approved China package insert * Documented patient with medical records

Exclusion criteria

* Previous treatment for diffuse large B-cell lymphoma or follicular lymphoma

Design outcomes

Primary

Measure	Time frame
Safety: Incidence of adverse events	4.5 years

Secondary

Measure	Time frame
Overall Response Rate (complete response + partial response)	4.5 years
Progression-free survival, defined as time from first treatment to lymphoma progression or death	4.5 years
Overall Survival, defined as time from 1st treatment to death of any cause	4.5 years

Countries

China

Outcome results